A randomized, open‐label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft‐tissue sarcoma

Background Therapeutic options for patients with advanced soft‐tissue sarcoma (STS) are limited. The goal of the current phase 2 study was to examine the clinical activity and safety of the combination of gemcitabine plus pazopanib, a multityrosine kinase inhibitor with activity in STS. Methods The...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2021-03, Vol.127 (6), p.894-904
Hauptverfasser:	Somaiah, Neeta, Van Tine, Brian Andrew, Wahlquist, Amy E., Milhem, Mohammed M., Hill, Elizabeth G., Garrett‐Mayer, Elizabeth, Armeson, Kent E., Schuetze, Scott M., Meyer, Christian F., Reuben, Daniel Y., Elias, Anthony D., Read, William L., Chawla, Sant P., Kraft, Andrew S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adverse events Aged Aged, 80 and over Anemia Anthracycline Antineoplastic Combined Chemotherapy Protocols - therapeutic use best overall response Confidence intervals Cross-Over Studies Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Docetaxel - administration & dosage Docetaxel - adverse effects Dosage Enzyme inhibitors Female Gemcitabine gemcitabine and pazopanib Health services Humans Hypertension Indazoles - administration & dosage Indazoles - adverse effects Inhibitor drugs Kinases Lymphopenia Male Median (statistics) Medical treatment Middle Aged Neutropenia Oncology Patients Pyrimidines - administration & dosage Pyrimidines - adverse effects Rank tests Safety Sarcoma Soft Tissue Neoplasms - drug therapy Soft Tissue Neoplasms - mortality soft‐tissue sarcoma Statistical analysis Sulfonamides - administration & dosage Sulfonamides - adverse effects Targeted cancer therapy Terminology Thrombocytopenia Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!